Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Safety, tolerability, pharmacokinetics and food effect of BI 3000202 in healthy adult men: a randomised placebo‑controlled single‑dose study

Investigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study examines how a new oral medication, BI 3000202, behaves in the bodies of healthy adult men. No specific disease is being treated; participants are volunteers without a related medical condition.

The purpose is to evaluate safety, tolerability, and the way the drug moves through the body (pharmacokinetics) at increasing dose levels, and to compare the amount of drug that reaches the bloodstream when taken with food versus on an empty stomach (bioavailability). Participants receive a single dose of either the study drug at one of several strengths (3 mg, 10 mg, 25 mg, or 250 mg) or a placebo in a blinded fashion, followed by blood sampling over 24 hours. In a separate part, the same participants take the drug as a tablet once with a standard meal and once without food, and blood is drawn to measure the drug concentration.

Safety checks include monitoring for any side effects that may be related to the medication, and blood tests are used to calculate measures such as the AUC (total exposure of the drug in the blood) and the highest concentration reached. The study lasts for a short period after each dose, with participants returning for follow‑up visits as needed.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit and baseline assessments

    After you join the study, you will attend an initial visit where you will sign the consent form and undergo basic health checks such as vital signs, blood tests, and a physical examination.

    The purpose of these assessments is to confirm that you meet the criteria for a healthy volunteer and to record your baseline measurements before any medication is taken.

  2. Step 2

    Randomisation and first single dose

    You will be randomly assigned to receive either an active tablet of BI 3000202 at a dose of 3 mg or a matching placebo tablet that contains no active ingredient.

    The tablet is taken orally with a glass of water, and it is a one‑time administration on the scheduled dosing day.

  3. Step 3

    Post‑dose observation and blood sampling

    After taking the tablet, you will remain at the study site for a monitoring period during which staff will check you for any adverse events (side effects).

    Blood samples will be collected at several time points over the next 24 hours to measure the amount of drug in your bloodstream and to assess safety.

  4. Step 4

    Washout period before next dose

    A washout period, during which no study medication is taken, will follow each dosing day to allow the previous dose to leave your body completely before the next dose is given.

  5. Step 5

    Subsequent single doses with increasing amounts

    You will repeat the same procedure for three higher dose levels: 10 mg, 25 mg, and 250 mg of BI 3000202.

    Each dose is taken as a single oral tablet, followed by the same 24‑hour blood‑sampling and safety monitoring as described for the first dose.

  6. Step 6

    Food effect part – fasting condition

    After completing the rising‑dose series, you will enter the food‑effect portion of the study.

    On the first food‑effect visit, you will fast for at least 10 hours (no food or drink except water) before taking a single 250 mg tablet of BI 3000202.

    Blood samples will again be taken over the next 24 hours to evaluate how the drug is absorbed when taken on an empty stomach.

  7. Step 7

    Food effect part – fed condition

    After another washout period, you will return for the second food‑effect visit.

    This time you will eat a standard high‑fat meal and, within 30 minutes after starting the meal, take another single 250 mg tablet of BI 3000202.

    The same 24‑hour blood‑sampling schedule will be used to compare drug absorption with food versus without food, which is called bioavailability.

  8. Step 8

    Final assessments and study completion

    Once all dosing visits are finished, you will undergo final safety checks, including a last set of vital signs and blood tests.

    The study staff will review the information collected during the trial and then you will be discharged from the study.

Who can join the trial?

4 criteria

  • Healthy male subjects as judged by the study doctor after a full medical history, a physical check‑up, measurement of vital signs (such as blood pressure and pulse rate), a 12‑lead ECG (a test that records the heart’s electrical activity), and lab tests, with no important health problems found.
  • Age between 18 and 45 years, inclusive.
  • Body mass index (BMI) from 18.5 to 29.9 kg/m². BMI is a simple calculation that compares weight to height to see if a person is underweight, normal weight, or overweight.
  • Signed and dated written informed consent following ICH‑GCP (International Council for Harmonisation Good Clinical Practice, which ensures the study is done safely and ethically) and local laws, completed before entering the trial.

Who cannot join the trial?

5 criteria

  • Abnormal medical exam results – If any part of the physical check‑up (including blood pressure (BP), pulse rate (PR), or an electrocardiogram (ECG) that records the heart’s electrical activity) is outside the normal range and the doctor believes it is important, you cannot take part.
  • Blood pressure or pulse rate outside set limits – If repeated measurements show a systolic blood pressure (the top number) lower than 90 mmHg or higher than 140 mmHg, a diastolic blood pressure (the bottom number) lower than 50 mmHg or higher than 90 mmHg, or a pulse rate (heart beats per minute) lower than 50 bpm or higher than 90 bpm, you are excluded.
  • Laboratory test results outside normal ranges – Any blood, urine or other lab test that falls outside the standard reference values and the investigator judges to be important will prevent participation.
  • Presence of another health condition – If you have any additional disease or health problem that the investigator considers relevant, you cannot join the study.
  • There may be additional exclusion reasons not listed here that could also prevent participation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

BI 3000202 is an experimental oral tablet being tested in healthy volunteers. In the study, participants take a single dose of the tablet to see how safe it is, how well people tolerate it, and how the body absorbs and processes the medicine. The trial also compares how much of the drug gets into the bloodstream when taken with food versus on an empty stomach, helping researchers understand if meals affect its effectiveness. This information will guide future studies and potential use of the medicine.

What is already known about the treatment

BI 3000202 - BI 3000202 is taken by mouth as a film‑coated tablet, with the trial testing single doses ranging from 3 mg to 250 mg. The substance is an investigational small‑molecule drug that is still in early clinical development and has not been approved for any medical use. It is being studied mainly to assess safety, how the body absorbs and processes it, and its potential use for conditions that may benefit from its targeted biological activity. BI 3000202 belongs to the class of oral experimental inhibitors that act on a specific molecular pathway, although the exact target is still being clarified.

Investigated diseases

Healthy volunteers - Individuals without known disease who take part in early‑phase clinical research to provide baseline information on safety and how the body processes a new drug.
Trial detailsLast updated 14 Oct 2026
Age18+ yearsPhasePhase ITrial ID2022-502424-43-00Protocol code1509-0001Estimated enrolment68 patientsSponsorBoehringer Ingelheim International GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.